ALT - Holzer & Holzer LLC Reminds Shareholders of July 5 2024 Lead Plaintiff Deadline in Altimmune Inc. (ALT) Class Action – Investors With Significant Losses Encouraged to Contact the Firm | Benzinga

ATLANTA, June 26, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company's business, operations, and prospects, including allegations that: (i) Altimmune overstated the potential for pemvidutide to stand out from competing GLP-1 agonists based on the drug's efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide's clinical, commercial, and competitive prospects than ...

ALT) Class Action – Investors With Significant Losses Encouraged to Contact the Firm>Full story available on Benzinga.com